Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Der Urologe. Ausg. A|November 25, 2011
[Second line therapy for castration-resistant prostate cancer (CRPC)]B Molitor, C Börgermann
Der Internist|October 30, 2007
[Differential therapy of prostate cancer]T Jäger, H Rübben, C Börgermann
Der Urologe. Ausg. A|January 5, 2007
[Palliative therapy concepts for patients with urothelial cancer of the urinary bladder]F Vom Dorp, C Börgermann, H Rübben
Annales De Gastroenterologie Et D'Hepatologie|January 1, 1988
[Current aspects of digestive actinomycoses. Apropos of a case of hepatic actinomycosis]P Bourée, M B Molitor
Der Urologe. Ausg. A|November 9, 2016
[Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study]T Reinhold, C Dornquast, C Börgermann, et al.
Hamostaseologie|August 23, 2005
[Monitoring of the heparin therapy during acute haemodialysis]B Molitor, R Klingel, G Hafner
Der Urologe. Ausg. A|January 6, 2007
[The management of cutaneous metastases]C Börgermann, F Vom Dorp, S Krege, et al.
Der Urologe. Ausg. A|August 21, 2009
[Free/total PSA ratio in clinical and ambulatory application. Are different cutoffs justified?]A Swoboda, H-J Luboldt, H Rübben, et al.
Der Urologe. Ausg. A|May 20, 2006
[Therapeutic options for hormone-refractory prostate cancer]K Miller, C Börgermann, J Thüroff, et al.
The Journal of Urology|December 23, 2000
Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 studyS Krege, V Rembrink, C Börgermann, et al.
Pageof 4